341 related articles for article (PubMed ID: 21497067)
41. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G
J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269
[TBL] [Abstract][Full Text] [Related]
42. Effects of linezolid on staphylococcal adherence versus time of treatment.
Pagano PJ; Buchanan LV; Dailey CF; Haas JV; Van Enk RA; Gibson JK
Int J Antimicrob Agents; 2004 Mar; 23(3):226-34. PubMed ID: 15164962
[TBL] [Abstract][Full Text] [Related]
43. Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in Brazil.
Kuti JL; Kiffer CR; Mendes CM; Nicolau DP
Clin Microbiol Infect; 2008 Feb; 14(2):116-23. PubMed ID: 18076672
[TBL] [Abstract][Full Text] [Related]
44. In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates.
Mendes RE; Moet GJ; Janechek MJ; Jones RN
Antimicrob Agents Chemother; 2010 Jun; 54(6):2704-6. PubMed ID: 20385851
[TBL] [Abstract][Full Text] [Related]
45. In vitro activity of linezolid in combination with doxycycline, fosfomycin, levofloxacin, rifampicin and vancomycin against methicillin-susceptible Staphylococcus aureus.
Sahuquillo Arce JM; Colombo Gainza E; Gil Brusola A; Ortiz Estévez R; Cantón E; Gobernado M
Rev Esp Quimioter; 2006 Sep; 19(3):252-7. PubMed ID: 17099793
[TBL] [Abstract][Full Text] [Related]
46. Telavancin: in vitro activity against staphylococci in a biofilm model.
Gander S; Kinnaird A; Finch R
J Antimicrob Chemother; 2005 Aug; 56(2):337-43. PubMed ID: 15972312
[TBL] [Abstract][Full Text] [Related]
47. Antibacterial activity of linezolid and vancomycin in an in vitro pharmacodynamic model of gram-positive catheter-related bacteraemia.
Wiederhold NP; Coyle EA; Raad II; Prince RA; Lewis RE
J Antimicrob Chemother; 2005 May; 55(5):792-5. PubMed ID: 15814598
[TBL] [Abstract][Full Text] [Related]
48. Pharmacokinetic/pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model.
Boak LM; Li J; Rayner CR; Nation RL
Antimicrob Agents Chemother; 2007 Apr; 51(4):1287-92. PubMed ID: 17242144
[TBL] [Abstract][Full Text] [Related]
49. [In vitro activity of linezolid against clinical isolates of methicillin-resistant Staphylococcus aureus].
Pérez L; Alarcón T; Jiménez S; de Las Cuevas MC; López-Brea S
Rev Esp Quimioter; 2001 Mar; 14(1):47-50. PubMed ID: 11376349
[TBL] [Abstract][Full Text] [Related]
50. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model.
LaPlante KL; Rybak MJ
Antimicrob Agents Chemother; 2004 Dec; 48(12):4665-72. PubMed ID: 15561842
[TBL] [Abstract][Full Text] [Related]
51. In vitro activity of telavancin and comparator antimicrobial agents against a panel of genetically defined staphylococci.
Farrell DJ; Krause KM; Benton BM
Diagn Microbiol Infect Dis; 2011 Mar; 69(3):275-9. PubMed ID: 21353951
[TBL] [Abstract][Full Text] [Related]
52. Extracellular and intracellular bactericidal activities of XF-70 against small-colony variant hemB mutants of meticillin-susceptible and meticillin-resistant Staphylococcus aureus.
Vaudaux P; Huggler E; Rhys-Williams W; Love WG; Lew DP
Int J Antimicrob Agents; 2011 Jun; 37(6):576-9. PubMed ID: 21414759
[TBL] [Abstract][Full Text] [Related]
53. Linezolid and quinupristin/dalfopristin resistance in vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus prior to clinical use in Turkey.
Baysallar M; Kilic A; Aydogan H; Cilli F; Doganci L
Int J Antimicrob Agents; 2004 May; 23(5):510-2. PubMed ID: 15120733
[TBL] [Abstract][Full Text] [Related]
54. High vancomycin minimum inhibitory concentrations with heteroresistant vancomycin-intermediate Staphylococcus aureus in meticillin-resistant S. aureus bacteraemia patients.
Wang JL; Lai CH; Lin HH; Chen WF; Shih YC; Hung CH
Int J Antimicrob Agents; 2013 Nov; 42(5):390-4. PubMed ID: 24041465
[TBL] [Abstract][Full Text] [Related]
55. Update on the telavancin activity tested against European staphylococcal clinical isolates (2009-2010).
Mendes RE; Sader HS; Farrell DJ; Jones RN
Diagn Microbiol Infect Dis; 2011 Sep; 71(1):93-7. PubMed ID: 21851873
[TBL] [Abstract][Full Text] [Related]
56. Activity of ceftaroline against extracellular (broth) and intracellular (THP-1 monocytes) forms of methicillin-resistant Staphylococcus aureus: comparison with vancomycin, linezolid and daptomycin.
Mélard A; Garcia LG; Das D; Rozenberg R; Tulkens PM; Van Bambeke F; Lemaire S
J Antimicrob Chemother; 2013 Mar; 68(3):648-58. PubMed ID: 23188792
[TBL] [Abstract][Full Text] [Related]
57. Activity of ceftobiprole compared with those of other agents against Staphylococcus aureus strains with different resistotypes by time-kill analysis.
Lin G; Appelbaum PC
Diagn Microbiol Infect Dis; 2008 Feb; 60(2):233-5. PubMed ID: 17997257
[TBL] [Abstract][Full Text] [Related]
58. The effect of inoculum size on selection of in vitro resistance to vancomycin, daptomycin, and linezolid in methicillin-resistant Staphylococcus aureus.
Rio-Marques L; Hartke A; Bizzini A
Microb Drug Resist; 2014 Dec; 20(6):539-43. PubMed ID: 25010140
[TBL] [Abstract][Full Text] [Related]
59. Enhanced activity of linezolid against Staphylococcus aureus in cerebrospinal fluid.
Schwameis R; Fille M; Manafi M; Zeitlinger M; Sauermann R
Res Microbiol; 2012 Apr; 163(3):157-60. PubMed ID: 22210435
[TBL] [Abstract][Full Text] [Related]
60. Ventriculitis due to a hetero strain of vancomycin intermediate Staphylococcus aureus (hVISA): successful treatment with linezolid in combination with intraventricular vancomycin.
Amod F; Moodley I; Peer AK; Sunderland J; Lovering A; Wootton M; Nadvi S; Vawda F
J Infect; 2005 Apr; 50(3):252-7. PubMed ID: 15780422
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
